AI Based Target Identification - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The aI based target identification market size was valued at USD 0.66 billion in 2025 and is estimated to grow from USD 0.86 billion in 2026 to reach USD 3.18 billion by 2031, at a CAGR of 26.94% during the forecast period (2026-2031). This report is Segmented by Component (Software and Services), Technology (Machine Learning, and More), Application (Target Identification & Validation, and More), Drug Type (Small Molecules, and More), Deployment (Cloud-Based, and On-Premise), Data Source (Omics Datasets, and More), Therapeutic Area (Oncology, and More), End User, and Geography. The Market and Forecasted in Terms of Value (USD).

Global AI Based Target Identification Market Trends and Insights

Rising Biopharma R&D Cost Pressures

Escalating discovery expenditures are forcing companies to front-load computational validation before wet-lab synthesis. AI based target identification market participants now use in-silico screening to evaluate millions of target-ligand pairs within weeks, shrinking preclinical workflows from up to six years to under two. The USD 1 billion partnership between Eli Lilly and NVIDIA illustrates how integrated GPU clusters accelerate model iteration and lower marginal compute costs. Cloud-delivered prediction services also let smaller biotechs adopt pay-per-inference pricing that aligns spend with milestones. Oncology and rare disease developers, where late-stage failure rates remain high, are the earliest adopters of this cost-containment strategy.

Expansion of High-Quality Biomedical Data Assets

Single-cell atlases, proteomic cohorts, and CRISPRi knockdown libraries are growing in scale and resolution, enabling foundation models to learn causal biology signals. Xaira Therapeutics trained its X-Cell model on 25.6 million perturbed transcriptomes, creating a 4.9 billion-parameter engine that predicts cellular responses to genetic perturbation. The Genetic and Neuropsychiatric Proteomics Consortium released data from 18,645 participants that link protein abundance to clinical phenotypes, giving neurology programs a human-centric evidence base. Continuous data generation through high-throughput phenomics and spatial transcriptomics forms a feedback loop where each cycle improves model accuracy.

Regulatory & AI Explainability Challenges

The FDA and EMA issued joint AI principles in January 2026 that emphasize data governance and risk-based oversight but stop short of codifying test metrics for foundation models. Sponsors, therefore, face case-by-case negotiations on acceptable evidence, elevating compliance costs. Deep neural networks with billions of parameters remain black boxes; companies such as Exscientia generate human-readable rationales, yet this adds latency and may lower predictive accuracy. Divergent regional guidance further complicates global submissions.

Other drivers and restraints analyzed in the detailed report include:

• Increasing Strategic Collaborations Between Pharma & AI Vendors
• Advancements in Cloud Computing & Generative AI
• Data Fragmentation & Lack of Standards

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Software retained 65.38% of 2025 revenue, yet services are set to grow at 27.21% CAGR through 2031 as CROs embed AI into discovery workflows. The AI based target identification market size for services is projected to expand rapidly as contract partners such as Infosys’ Indivi and Inotiv scale pay-per-target offerings. Traditional license fees of USD 0.5 million to USD 2 million per year are being augmented by end-to-end discovery contracts exceeding USD 10 million, lifting vendor lifetime value.

CRO adoption also addresses the talent scarcity restraint: mid-sized biotechs outsource computational biology to service providers rather than building in-house teams. Hybrid models are emerging; Exscientia offers both SaaS access and full-service target discovery, while Recursion’s OS 4.0 adds morphology-based profiling to partner projects. As services mature, margin pressure on pure-software vendors may intensify unless they differentiate with proprietary datasets.

Machine learning represented 45.17% of spending in 2025, but natural language processing (NLP) is climbing at 29.47% CAGR as it mines over 30 million PubMed abstracts and 15 million patents for latent associations. BioGPT, PubMedBERT, and other biomedical LLMs sift unstructured text to surface target-disease linkages that structured omics data miss. Computer vision contributes a smaller share, yet platforms such as Recursion analyze 50 billion cellular images to identify phenotype-driven targets.

The AI based target identification market share for NLP solutions is enlarging because literature-centric discovery scales cheaply once models are pre-trained. Convergence between NLP and generative diffusion models now allows reasoning across multi-modal inputs, accelerating hypothesis generation from months to days. Quantum machine learning remains experimental, with early pilots at Boehringer Ingelheim exploring protein folding algorithms on quantum hardware.

Target identification and validation held 34.83% of 2025 revenue, yet hit generation is forecast to advance at 28.56% CAGR through 2031. The AI based target identification market size for hit-generation tools is swelling because generative chemistry engines can design de novo molecules that meet binding and developability constraints concurrently. Insilico advanced three AI-generated compounds into clinical trials by 2025, validating the approach.

Drug repurposing gains traction as platforms link real-world evidence to existing molecules; BenevolentAI’s knowledge graph surfaced baricitinib for COVID-19, leading to emergency use authorization. Integrated safety prediction during target selection is becoming mandatory after the FDA urged sponsors to include in-silico toxicity assessments in the 2025 draft guidance.

Complete Report Scope:

• By Component
  • Software
  • Services
• By Technology
  • Machine Learning
  • Natural Language Processing (NLP)
  • Computer Vision
  • Quantum Machine Learning
  • Others
• By Application
  • Target Identification & Validation
  • Hit Generation & Prioritization
  • Drug Repurposing
  • Pre-clinical Safety & Toxicity Assessment
  • Others
• By Drug Type
  • Small Molecules
  • Biologics
  • Gene & Cell Therapies
  • PROTACs & Degraders
  • Others
• By Deployment
  • Cloud-Based
  • On-Premise
• By Data Source
  • Omics Datasets
  • EHR & Clinical Data
  • Real-world & Claims Data
  • Others
• By Therapeutic Area
  • Oncology
  • Neurology
  • Immunology
  • Infectious Diseases
  • Others
• By End User
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.55% of 2025 revenue, supported by FDA regulatory leadership, venture capital density, and hyperscaler infrastructure. Eli Lilly’s USD 1 billion NVIDIA collaboration showcases Silicon Valley’s GPU advantage. Canada positions itself as a cost-effective AI hub through favorable R&D tax incentives backing Sanofi’s Toronto center. Mexico remains oriented to trial execution but is attracting near-shoring discovery spend.

Asia-Pacific is projected to grow at 35.24% CAGR, propelled by China’s sovereign AI strategy, Japan’s pharma-AI alliances, and India’s CRO modernization. XtalPi’s 201% revenue jump in 2025 proves the commercial viability of full-stack AI discovery. AstraZeneca’s USD 5.3 billion CSPC deal signals global validation of Chinese AI platforms. India’s Veeda-Mango tie-up blends EHR phenotypes with molecular datasets to win multinational business.

Europe maintains a significant share, guided by the EMA reflection paper that balances innovation with explainability. Germany’s Boehringer Ingelheim is piloting quantum protein algorithms, while the United Kingdom’s BenevolentAI progresses multiple candidates into preclinical validation. GCC states invest in sovereign life-science clusters under the NEOM umbrella to diversify oil economies. South America remains the smallest region, yet Brazil’s rare-disease initiatives are beginning to incorporate AI target discovery.

List of Companies Covered in this Report:

• Arpeggio Bio
• Atomwise Inc.
• Benevolent AI
• BioAge Labs
• CelerisTx
• Cyclica (Recursion)
• DeepCure
• Evaxion Biotech
• Exscientia PLC
• Genesis Therapeutics
• HotSpot Therapeutics
• Insilico Medicine
• Isomorphic Labs
• NVIDIA BioNeMo
• Peptilogics
• Recursion Pharmaceuticals Inc.
• Turbine AI
• Valo Health
• Verge Genomics
• Xaira Therapeutics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support